Skip to main content
Livermore
Livermore
ZHEN

Protalix BioTherapeutics, Inc.

PLX
Exchange
NYSE
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001006281

No open-market purchases or sales by Protalix BioTherapeutics, Inc. insiders were filed in the last 90 days; 101 institutions reported holding it in 13F filings for Q2 2026, worth $33.7M in total; no superinvestor holds it.

Q2 2022 vs. Q1 2022

How the institutions holding Protalix BioTherapeutics, Inc. changed between Q1 2022 and Q2 2022.

All holders in Q2 2022All holders in Q1 2022

13F holders of PLX: Q1 2022 compared with Q2 2022
MeasureQ1 2022Of which not filed for Q2 2022Q2 2022Change
Holders32130−1
Shares1.22M41.6K1.19M+17.1K (+1.5%)
Value$1.29M$44.0K$1.30M+$53.4K (+4.3%)

1 institution that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so the changes leave them out.

New holders (4)

Institutions that held Protalix BioTherapeutics, Inc. at the end of Q2 2022 but not at the end of Q1 2022.

Institutions new to PLX in Q2 2022
InstitutionSharesValue% of portfolio
Citadel Advisors LLC59,915$65.0K0.00%
Two Sigma Investments, LP25,510$28.0K0.00%
Capital Performance Advisors LLP25,974$28.0K0.02%
Millennium Management LLC19,223$21.0K0.00%

Sold out (5)

Institutions that held Protalix BioTherapeutics, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.

Institutions that sold out of PLX in Q2 2022
InstitutionShares, Q1 2022Value, Q1 2022
Phoenix Holdings Ltd.244,113$259.0K
Group One Trading, L.P.32,646$35.0K
Susquehanna International Group, LLP12,119$13.0K
Tower Research Capital LLC (TRC)6,465$7.00K
Citigroup Inc300$0

Not filed for Q2 2022 yet (1)

Institutions that held Protalix BioTherapeutics, Inc. at the end of Q1 2022 and haven't filed a 13F for Q2 2022. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding PLX in Q1 2022 that haven't filed for Q2 2022
InstitutionShares, Q1 2022Value, Q1 2022
Susquehanna Fundamental Investments, LLC41,574$44.0K